Wednesday 22 February 2017

Faculté de Pharmacie
3, rue du Professeur Laguesse
BP83 - 59006 - Lille Cedex
Tél. : +33 (0)3 20 96 40 40
Fax : +33 (0)3 20 95 90 09


Université Lille Nord de France
College of Pharmacy
3, rue du Professeur Laguesse
59006 Lille, France

Tel: +33-3-20964975
Fax: +33-3-20964995
Télécharger le fichiercontact


2nd European Conference on Pharmaceutics: "Novel Dosage Forms, Innovative Technologies"

April 3-4, 2017, Krakow, Poland

Lien externe - Ouverture dans une nouvelle fenêtre


2nd BIOMAT Congress

June 12-16, 2017, Ambleteuse, France

Lien externe - Ouverture dans une nouvelle fenêtre


Workshop on Oral Controlled Release

July 6, 2017, Lille, France

Lien externe - Ouverture dans une nouvelle fenêtre



February - 2017
Su Mo Tu We Th Fr Sa
  01 02 03 04
05 06 07 08 09 10 11
12 13 14 15 16 17 18
19 20 21 23 24 25
26 27 28  

INSERM U1008: Controlled Drud Delivery Systems and Biomaterials

Numerous drug candidates fail to show in vivo efficacy. This can be attributed to their physicochemical properties and / or pharmacokinetics / pharmacodynamics, in particular poor aqueous solubility, poor permeability across biological barriers, rapid drug elimination out of the living body and/or narrow therapeutic windows. Even if the substance exhibits an ideal chemical structure allowing for optimal therapeutic effects, the therapy fails if the drug cannot reach its site of action in the human body.

Our aim is to overcome these restrictions and to develop novel types of advanced drug delivery systems and biomaterials allowing for an accurate control of the resulting drug release kinetics during periods ranging from a few minutes up to several years. Thus, the drug can effectively be protected in the human body and potentially administered directly at its site of action. We work on different types of systems, in particular:

• Coated pellets which are orally administered and allow for site specific drug delivery to the colon. This is of major benefit for the treatment of inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis

• Biodegradable microparticles for parenteral administration, especially for the treatment of brain diseases (e.g., cancer and neurodegenerative disorders)

• Lipid implants for the controlled delivery of fragile protein drugs (e.g., growth factors)

• Drug eluting stents with improved biocompatibility

• Implants releasing antibiotics and anesthetics in a time controlled manner for dental surgery

• Scaffolds releasing incorporated drugs at a pre-determined rate for bone substitution in facial surgery.

INSERM U1008 - Key methods & aims of the research group

We prepare the different types of advanced drug delivery systems and biomaterials using a broad range of techniques, for instance via direct compression of drug-polymer blends, fluidized bed coating, extrusion, and freeze drying. The devices are thoroughly characterized in vitro with a large variety of physicochemical and biological methods (e.g., in vitro drug release measurements, differential scanning calorimetry, size exclusion chromatography, mechanical analysis, cell culture tests, biocompatibility and bioerosion studies). Furthermore, the pharmacokinetics and pharmacodynamics of the drugs are determined in vivo (animal models and clinical trials).

Based on these experimental results, novel mathematical theories are developed allowing for the elucidation of the underlying drug release mechanisms and for the quantitative prediction of the effects of formulation and processing parameters on the resulting drug release kinetics. Thus, the optimization of the novel drug delivery systems and biomaterials can be facilitated. Furthermore, we establish in vitro – in vivo correlations, in particular with respect to the drug release kinetics. This allows to reduce the number of required animal studies and to improve the safety of the novel pharmaco-therapies.



Page updated on 02/02/2017 (20h41)
Flux rss actualités